Combination therapy for EGFR-mutant lung cancer with brain metastases
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, sacituzumab tirumotecan and bevacizumab, for people with EGFR-mutant lung cancer that has spread to the brain. It aims to see if this combination can shrink tumors and improve outcomes after standard EGFR inhibitor treatment has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old.
- You must have a type of lung cancer called nonsquamous non-small cell lung cancer that has an EGFR mutation.
- Your cancer must have grown while on a third-generation EGFR inhibitor (like osimertinib).
- You must have brain metastases that are either causing no symptoms or are controlled with local treatment and stable for at least 2 weeks.
- You should be able to take care of yourself (ECOG score 0 or 1).
- You must not have had certain prior treatments like chemotherapy or topoisomerase inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a combination of two drugs—Sac-TMT (an antibody-drug conjugate that targets tumor cells) and bevacizumab (a drug that blocks blood vessel growth to tumors)—as a second-line treatment for advanced non-squamous non-small cell lung cancer. The goal is to see if this combination can help people whose cancer has progressed after initial chemotherapy and immunotherapy.
This study tests a new combination of drugs (sacituzumab tirumotecan plus a third-generation EGFR inhibitor) with or without radiation therapy for advanced lung cancer that has spread to the brain after prior EGFR inhibitor treatment. The goal is to see if this combination can better control the cancer and improve outcomes for patients with brain metastases.
This trial studies a new drug called sacituzumab tirumotecan combined with brain radiation for people with EGFR-positive lung cancer that has spread to the brain and has grown despite targeted therapy. The goal is to see if this combination can better control the brain tumors.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
This trial tests a combination of two drugs, sacituzumab govitecan and bevacizumab, for people with a specific type of lung cancer (non-squamous) that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
This study tests a new combination of two drugs (sacituzumab tirumotecan and another drug) for people with advanced esophageal cancer. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.